Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival

Advanced non-small-cell lung carcinomas (NSCLCs) with activating EGFR mutations initially respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) [1 –3]. However, most patients usually progress after 12 months of treatment [4,5]. Various mechanisms are involved in acquired resistance to EGFR-TKIs, including EGFR T790M secondary mutation, MET gene amplification, HER2 gene amplification, and histologic changes such as small-cell lung carcinoma ( SCLC) transformation [4–6].

Source: Lung Cancer - April 17, 2018 Category: Cancer & Oncology Authors: Jin Woo Joo, Min Hee Hong, Hyo Sup Shim Source Type: research